Abstract:Background and Objective High‐grade glioma (HGG) is known to be characterized by a high degree of malignancy and a worse prognosis. The classical treatment is safe resection supplemented by radiotherapy and chemotherapy. Tumor treating fields (TTFields), an emerging physiotherapeutic modality that targets malignant solid tumors using medium‐frequency, low‐intensity, alternating electric fields to interfere with cell division, have been used for the treatment of new diagnosis of glioblastoma, however, their administration in HGG requires further clinical evidence. The efficacy and safety of TTFields in Chinese patients with HGG were retrospectively evaluated by us in a single center. Methods We enrolled and analyzed 52 patients with newly diagnosed HGG undergoing surgery and standard chemoradiotherapy regimens from December 2019 to June 2022, and followed them until June 2023. Based on whether they used TTFields, they were divided into a TTFields group and a non‐TTFields group. Progression‐free survival (PFS) and overall survival (OS) were compared between the two groups. Results There were 26 cases in the TTFields group and 26 cases in the non‐TTFields group. In the TTFields group, the median PFS was 14.2 months (95% CI: 9.50–18.90), the median OS was 19.7 months (95% CI: 14.95–24.25) , the median interval from surgery to the start of treatment with TTFields was 2.47 months (95% CI: 1.47–4.13), and the median duration of treatment with TTFields was 10.6 months (95% CI: 9.57–11.63). 15 (57.69%) patients experienced an adverse event and no serious adverse event was reported. In the non‐TTFields group, the median PFS was 9.57 months (95% CI: 6.23–12.91) and the median OS was 16.07 months (95% CI: 12.90–19.24). There was a statistically significant difference in PFS (p = 0.005) and OS (p = 0.007) between the two groups. Conclusions In this retrospective analysis, TTFields were observed to improve newly diagnosed HGG patients' median PFS and OS. Compliance was much higher than reported in clinical trials and safety remained good.

Diagnosis and Treatment of Glioma (report of 296 Cases)

Therapeutic Effects and Quality of Life in 37 Glioma Patients with Postoperative Intensity-Modulated Radiotherapy

Implementation Of Clinical Practice Guidelines For Newly Diagnosed Gbm Patients In China.

Clinical Study of Mailgnant Brain Gliomas Treated by Interstitial Radiotherapy and Interstitial Chemotherapy

Surgical Treatment for Intramedullary Spinal Cord Tumors:56 Cases Experience

Diagnosis and management of multiple high-grade gliomas: a retrospective study

[Neuroimaging diagnosis and therapeutic efficacy of different surgical methods of gliomatosis cerebri]

Surgical treatment of gliomatosis cerebri

Prognostic Evaluations of Recurrent Gliomas and Preliminary Efficacies of Combined Modality Therapy

Diagnosis and treatment of early-stage glioblastoma

Analysis of the factors affecting the prognosis of glioma patients

High-grade Thalamic Gliomas: Microsurgical Treatment and Prognosis Analysis

Current Status of Cerebral Glioma Surgery in China.

Management of Tectal Gliomas:Review of Twelve Cases

Microsurgical management and prognosis of primary spinal cord glioblastoma

Surgical Therapy Progress of Low Grade Gliomas

Research Progress on Radiotherapy Technology and Dose Fraction Scheme for Advanced Gliomas

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields

Diagnosis and Treatment of Intracranial Germ Cell Tumors (Clinical Analysis of 38 cases)

Characteristics and Microsurgical Treatment of Glioma in Limbic System

Tumor treating fields for newly diagnosed high‐grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center